Mesothelioma Blood Tests and Biomarkers

Mesothelioma Biomarkers
Blood-Based Diagnostic and Monitoring Tests
Category	Medical / Diagnostic
FDA-Approved Test	MESOMARK (SMRP)
MESOMARK Sensitivity	61% (pooled)
MESOMARK Specificity	87% (pooled)
Most Accurate Panel	SOMAmer 13-protein (AUC 0.95)
Biomarkers Under Study	7+ markers
Key Limitation	No single marker sufficient alone
Free Case Review →

Blood-based biomarkers offer a minimally invasive approach to detecting, monitoring, and prognosticating malignant mesothelioma — an aggressive cancer with a median survival of approximately 12 months from diagnosis. Fewer than 5% of mesothelioma patients are diagnosed at stage I, making early detection through blood tests a critical area of research. The MESOMARK assay — measuring soluble mesothelin-related peptides (SMRP) — is the only FDA-approved blood biomarker for mesothelioma, cleared in 2007 for monitoring treatment response in already-diagnosed patients. Meta-analyses of 28 studies report a pooled sensitivity of 61% and specificity of 87%. Emerging biomarkers including fibulin-3, hyperacetylated HMGB1, and the 13-protein SOMAmer panel show higher accuracy in research settings, with the strongest evidence supporting multi-biomarker panels rather than any single marker.

Mesothelioma blood tests and biomarkers at a glance:

• MESOMARK: only FDA-approved test — cleared in 2007 for monitoring treatment response, with 61% pooled sensitivity and 87% specificity across 28 studies
• Soluble mesothelin 0.3 nM detection limit — SMRP levels correlate directly with tumor volume, enabling less invasive treatment monitoring than imaging
• Fibulin-3 AUC of 0.94 in serum — outperforms SMRP (AUC 0.81) and osteopontin (AUC 0.83) in head-to-head comparisons
• Osteopontin 57% sensitivity — patients with serum levels above 350 ng/mL had median survival of only 5 months versus 15 months for low levels
• HMGB1 100% sensitivity/specificity — hyperacetylated isoform discriminated all 22 mesothelioma patients from 20 asbestos-exposed controls in initial study
• SOMAmer 13-protein panel AUC 0.95 — the most accurate multi-marker classifier, detecting 88% of stage I/II disease with 93.2% sensitivity
• Three-marker combo AUC 0.99 — mesothelin plus fibulin-3 plus HMGB1 achieved 96% sensitivity and 93% specificity in combination
• MPF 50% reduction threshold — patients achieving this decrease during treatment had median overall survival of 22.3 versus 8.8 months
• miRNA 0% prediagnostic sensitivity — circulating microRNAs failed to detect mesothelioma in samples collected a median 8.9 months before clinical diagnosis
• Renal disease false positives — both mesothelin and MPF levels are elevated in decreased kidney function independent of malignancy, a major confounding factor

Key Facts

Key Facts: Mesothelioma Blood Tests and Biomarkers

Only FDA-approved test: MESOMARK assay (SMRP) — cleared in 2007 by Fujirebio Diagnostics MESOMARK sensitivity: 61% pooled across 28 studies; specificity 87% Best single marker: Fibulin-3 with AUC of 0.94 in serum-based studies Most accurate panel: SOMAmer 13-protein classifier — AUC 0.95, detecting 88% of stage I/II disease HMGB1 potential: Hyperacetylated HMGB1 showed 100% sensitivity and specificity in initial study (small sample, expression of concern published) Limitation: No single biomarker is sufficient for definitive mesothelioma diagnosis alone False positive causes: Renal disease, other cancers (pancreatic, ovarian), and inflammatory conditions can elevate biomarker levels MESOMARK purpose: Approved for monitoring — NOT for primary diagnosis or screening miRNA limitation: Fails to detect mesothelioma in prediagnostic samples (0% sensitivity at 98% specificity) Combination approach: Mesothelin + fibulin-3 + HMGB1 panel achieved AUC of 0.99 with 96% sensitivity MPF prognostic value: Patients with ≥50% MPF reduction during treatment had median OS of 22.3 vs. 8.8 months Tissue biopsy: Remains required for definitive diagnosis — biopsy procedures confirm histologic subtype

What Is the MESOMARK Assay?

The MESOMARK assay is an enzyme-linked immunosorbent assay (ELISA) for the quantitative measurement of soluble mesothelin-related peptides (SMRP) in human serum. Mesothelin is a 71-kDa precursor protein that is cleaved into two products: the 31-kDa N-terminal megakaryocyte potentiating factor (MPF) and a 40-kDa C-terminal glycoprotein. After further processing, SMRP is released from the cell surface. SMRP levels correlate directly with tumor volume, permitting less invasive monitoring of treatment response than imaging alone.

Developed by Fujirebio Diagnostics, Inc., MESOMARK received FDA clearance through a Humanitarian Device Exemption in January 2007. It remains the only FDA-approved serum biomarker test for mesothelioma and is available through reference laboratories such as ARUP Laboratories. The assay has an analytical sensitivity of 0.3 nM with a dynamic range extending to approximately 26.69 nM.

Sensitivity and Specificity

Meta-analytic evidence provides the most robust performance estimates for MESOMARK:

Study	Sensitivity	Specificity	AUC
Meta-analysis of 28 serum studies	61%	87%	0.806
12-study meta-analysis (717 MM, 2,851 controls)	64%	89%	—
Hollevoet individual patient data (16 studies)	32% (at 95% specificity)	95%	—
Pleural fluid SMRP (pooled)	79%	—	—

SMRP performs best for the epithelioid histological subtype and may remain at normal levels even in patients with sarcomatoid mesothelioma. Pleural fluid SMRP has higher sensitivity (79%) compared to serum (61%), but obtaining pleural fluid requires thoracentesis rather than a simple blood draw.

"MESOMARK is a valuable tool for tracking treatment response in patients already diagnosed with mesothelioma, but patients and families should understand it is not designed as a screening test for undiagnosed individuals — even those with known asbestos exposure history."

— David Foster, Patient Advocate, Danziger & De Llano

What Is Fibulin-3 and How Does It Compare to MESOMARK?

Fibulin-3 is a secreted glycoprotein encoded by the EFEMP-1 gene, involved in regulating mesothelioma cell proliferation and migration. First proposed as a mesothelioma biomarker by Pass et al. in a landmark 2012 New England Journal of Medicine study, the initial report was extraordinary: 96.7% sensitivity and 95.5% specificity for distinguishing mesothelioma from controls. However, subsequent validation studies produced highly variable results.

Meta-analyses have tempered the initial enthusiasm while confirming fibulin-3's potential superiority over SMRP. A meta-analysis of 7 studies (468 MM cases) found pooled sensitivity of 62% and specificity of 82% (AUC 0.81). However, serum-based assays showed notably better performance than plasma-based assays — sensitivity of 77% versus 54%, specificity of 85% versus 77%, and AUC of 0.92 versus 0.69 — suggesting sample type significantly affects diagnostic accuracy.

In head-to-head comparisons, the AUC for blood fibulin-3 (0.94) exceeded that of both SMRP (0.81) and osteopontin (0.83). The DIAPHRAGM prospective multicenter study was designed to definitively validate these findings. A key limitation remains the variability between studies, with some reporting sensitivity as low as 12.7–59%.

What Role Does Osteopontin Play in Mesothelioma Diagnosis?

Osteopontin (OPN) is a secreted glycoprotein involved in cell-matrix interaction and tumor migration. Pass et al. (2005) first linked elevated serum OPN to mesothelioma, reporting 77.6% sensitivity and 85.5% specificity. A subsequent meta-analysis of seven publications with ten studies established pooled sensitivity of 57%, specificity of 81%, and AUC of 0.85.

Osteopontin also carries prognostic significance: patients with high serum levels (>350 ng/mL) had median survival of only 5 months compared to 15 months for patients with low levels. However, OPN is elevated in multiple other cancers — including colon, lung, breast, and prostate cancer — limiting its specificity for mesothelioma. Plasma OPN outperforms serum OPN for diagnostic purposes because thrombin-related protein degradation during serum processing reduces accuracy.

What Is Megakaryocyte Potentiating Factor?

Megakaryocyte potentiating factor (MPF) is a 31-kDa secreted cytokine produced from the same MSLN gene precursor protein as mesothelin/SMRP. When the 71-kDa mesothelin precursor is cleaved by furin, it yields the N-terminal MPF and the C-terminal membrane-bound mesothelin. A prospective multicenter study of 507 participants found that both SMRP and MPF differentiated mesothelioma patients from controls (P<0.001), with no significant difference between the two markers (AUC: SMRP 0.871, MPF 0.849).

MPF shows particular promise as a prognostic biomarker and potential companion diagnostic for mesothelin-targeted immunotherapies. Elevated serum MPF predicts poor survival (HR 2.46, P=0.003), and in refractory mesothelioma, elevated MPF was an even stronger predictor (HR 6.12, P=0.0007). Patients receiving mesothelin-targeted therapy who achieved a ≥50% reduction in MPF had dramatically improved progression-free survival (median 11.3 vs. 1.9 months) and overall survival (22.3 vs. 8.8 months, P=0.004).

What Is the SOMAmer 13-Protein Classifier?

The SOMAmer (Slow Off-rate Modified Aptamer) proteomic panel represents the most promising multi-biomarker approach for mesothelioma detection. Developed by SomaLogic using the SOMAscan platform — which simultaneously measures over 1,000 proteins in unfractionated biological samples — researchers discovered 64 candidate biomarkers and derived a 13-marker random forest classifier from multicenter studies of 117 MM patients and 142 asbestos-exposed controls.

Validation Phase	AUC	Key Finding
Training set	0.99 ± 0.01	Near-perfect discrimination
Blinded verification	0.98 ± 0.04	Maintained in independent set
Blinded validation	0.95 ± 0.04	Confirmed in real-world conditions
Combined (sensitivity/specificity)	—	93.2% sensitivity, 90.8% specificity

The 13 classifier proteins — 9 upregulated and 4 downregulated — had not previously been associated with mesothelioma. Their functions fall into two groups: regulation of proliferation and inflammation. This multiplex approach far outperformed single-marker mesothelin testing (AUC 0.82, sensitivity 66%, specificity 88%) in the same populations. The DIAPHRAGM prospective multicenter study was designed to validate the SOMAmer panel in a clinically relevant setting.

What Is Hyperacetylated HMGB1?

High-Mobility Group Box 1 (HMGB1) is a damage-associated molecular pattern protein that plays a central role in asbestos carcinogenesis. When asbestos fibers lodge in the pleura, mesothelial cells undergo programmed necrosis and release non-acetylated HMGB1, triggering chronic inflammation. Mesothelioma cells become dependent on HMGB1, actively secreting the hyperacetylated isoform to sustain their own growth.

In a 2016 study published in Clinical Cancer Research, Napolitano, Carbone, and Pass measured HMGB1 isoforms in MM patients (n=22), asbestos-exposed individuals (n=20), and healthy controls (n=20). At a cutoff of 2.00 ng/mL, hyperacetylated HMGB1 discriminated MM patients from asbestos-exposed individuals with 100% sensitivity and 100% specificity (AUC 1.000). Total HMGB1 distinguished asbestos-exposed individuals from healthy controls with AUC of 0.964, and levels did not vary with tumor stage — suggesting potential for early detection.

Important Caveats

An expression of concern was published in 2020 regarding the integrity of mass spectrometry data contributed by one co-author. The small sample size (22 MM patients) raises the risk of data overfitting, and independent large-scale validation has not yet been completed. Potential confounders include alcoholic liver disease, which can elevate hyperacetylated HMGB1, though distinguishable by phosphorylation patterns. NCI-EDRN-funded validation studies were planned.

Can MicroRNAs Detect Mesothelioma Early?

MicroRNAs (miRNAs) are small non-coding RNAs (18–22 nucleotides) that are stable in blood and have been investigated as potential mesothelioma biomarkers. Several individual miRNAs show promise: miR-103a-3p achieved 83% sensitivity and 71% specificity for MPM versus asbestos-exposed controls, and when combined with mesothelin, sensitivity reached 95% with 81% specificity. A 6-miRNA prognostic signature predicted long survival after surgery with 92.3% accuracy.

However, miRNAs have a critical limitation for early detection. A nested case-control study using prediagnostic plasma samples (collected median 8.9 months before clinical diagnosis) found that miR-132-3p, miR-126-3p, and miR-103a-3p showed 0% sensitivity at 98% specificity for detecting mesothelioma prior to clinical diagnosis. By contrast, protein biomarkers such as mesothelin and calretinin detected the tumor in prediagnostic samples up to 15 months before clinical diagnosis with 46% sensitivity. This suggests miRNAs may be useful for prognosis in patients with established disease but fail at truly early detection.

What Are the Limitations of Blood-Based Biomarkers?

No single biomarker has achieved sufficient sensitivity and specificity to serve as a standalone diagnostic tool for mesothelioma. A systematic review concluded that no serum or pleural fluid biomarker could be recommended for routine clinical practice at this time, though falling SMRP may correlate with treatment response.

False Positive Causes

Several conditions can produce falsely elevated biomarker levels and must be considered when interpreting results:

• Renal disease: Both mesothelin/SMRP and MPF levels are elevated in patients with decreased kidney function, independent of malignancy. Renal dysfunction is a major predictor of false-positive mesothelin and calretinin results
• Other cancers: Mesothelin is overexpressed in pancreatic adenocarcinoma, ovarian cancer, and lung cancer. Osteopontin is elevated in colon, breast, prostate, and lung cancer
• Inflammatory conditions: Hypertension, bronchitis, and elevated inflammatory markers can affect mesothelin concentrations
• Age: A 10-year increase in age results in approximately 2-fold more false-positive mesothelin tests

Clinical covariates including age, BMI, and glomerular filtration rate independently affect SMRP and MPF levels and should be routinely recorded when interpreting these biomarkers.

What Is the Future of Mesothelioma Blood Testing?

The strongest evidence supports using biomarker panels rather than individual markers. A combination of fibulin-3 and HMGB1 achieved AUC of 0.987 for distinguishing mesothelioma from other pleural effusions (95.45% sensitivity, 92.11% specificity). A three-protein panel of mesothelin, fibulin-3, and HMGB1 achieved AUC of 0.99 with 96% sensitivity and 93% specificity. The 13-protein SOMAmer classifier demonstrated 92% overall accuracy with detection of 88% of early-stage disease.

The combination of protein biomarkers, miRNAs, and methylated DNA from different molecular classes represents the most promising path toward reliable early detection of mesothelioma in high-risk populations — particularly workers with documented asbestos exposure who are under medical surveillance through screening programs.

⚠ Statute of Limitations Warning: Filing deadlines vary by state from 1-6 years from diagnosis. Texas allows 2 years from diagnosis or discovery. Contact an attorney immediately to preserve your rights.

Related Resources

• Mesothelioma Diagnosis and Staging
• Mesothelioma Biopsy Procedures
• Mesothelioma Molecular and Genetic Testing
• Mesothelioma Treatment Options
• Mesothelioma Clinical Trials
• Understanding Your Diagnosis

Free, Confidential Case Evaluation Call (866) 222-9990 or visit dandell.com/contact-us No upfront fees • Experienced representation • National practice